PMV Pharmaceuticals Inc

NASDAQ:PMVPUnited States

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.

Contact Information

Headquarters

400 Alexander Park Drive, Suite 301PRINCETON, NJ, United States 08540

Phone

609-642-6670

Fax

302-636-5454

Executives

Independent Chairman of the Board

Richard Heyman

President, Chief Executive Officer, Co-Founder, Director

David Mack

Chief Financial Officer

Michael Carulli

Chief Development Officer

Deepika Jalota

Director

Arnold Levine